Is there a preferential approach for systemic therapy for triple negative breast cancer patients with leptomeningeal disease?

There are very few data on effective systemic therapies for triple negative leptomeningeal disease (LMD), mostly from case reports and small series. Much of the larger series are from unselected solid tumors and have focused on intrathecal therapy. However, it is generally recognized that systemic t...